Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Radioimmunotherapy of micrometastases: sidestepping the solid-tumor hurdle.

Literature DB >> 7562063

Radioimmunotherapy of micrometastases: sidestepping the solid-tumor hurdle.

G Sgouros.

Abstract

Entities: Disease

Mesh：

Year: 1995 PMID： 7562063

Source DB: PubMed Journal: J Nucl Med ISSN： 0161-5505 Impact factor: 10.057

Keyword Cloud
Cited

× No keyword cloud information.

7 in total

Review 1. The potential complementary role of targeted alpha therapy in the management of metastatic melanoma.

Authors: Michael P Brown; Eva Bezak; Barry J Allen
Journal: Melanoma Manag Date: 2015-11-24

2. Feasibility of 186Re-radioimmunotherapy for treatment in an adjuvant setting of colon cancer.

Authors: Seigo Kinuya; Kunihiko Yokoyama; Mishiroku Izumo; Takami Sorita; Takashi Obata; Hirofumi Mori; Kazuhiro Shiba; Naoto Watanabe; Noriyuki Shuke; Takatoshi Michigishi; Norihisa Tonami
Journal: J Cancer Res Clin Oncol Date: 2003-07-09 Impact factor: 4.553

3. Adjuvant radioimmunotherapy trial with iodine-131-labeled anti-carcinoembryonic antigen monoclonal antibody F6 F(ab')2 after resection of liver metastases from colorectal cancer.

Authors: Marc Ychou; David Azria; Cathy Menkarios; Patrick Faurous; François Quenet; Bernard Saint-Aubert; Philippe Rouanet; Monique Pèlegrin; Caroline Bascoul-Mollevi; Dominique Guerreau; Jean-Claude Saccavini; Jean-Pierre Mach; Jean-Claude Artus; André Pèlegrin
Journal: Clin Cancer Res Date: 2008-06-01 Impact factor: 12.531

4. Intratumour injection of immunoglobulins labelled with the alpha-particle emitter 211At: analyses of tumour retention, microdistribution and growth delay.

Authors: R H Larsen; O S Bruland
Journal: Br J Cancer Date: 1998-04 Impact factor: 7.640

Radioimmunotherapy of micrometastases: sidestepping the solid-tumor hurdle.

Review 1. The potential complementary role of targeted alpha therapy in the management of metastatic melanoma.

2. Feasibility of 186Re-radioimmunotherapy for treatment in an adjuvant setting of colon cancer.

3. Adjuvant radioimmunotherapy trial with iodine-131-labeled anti-carcinoembryonic antigen monoclonal antibody F6 F(ab')2 after resection of liver metastases from colorectal cancer.

4. Intratumour injection of immunoglobulins labelled with the alpha-particle emitter 211At: analyses of tumour retention, microdistribution and growth delay.

Review 5. Targeted alpha anticancer therapies: update and future prospects.

6. Orthotopic xenografts of human melanoma and colonic and ovarian carcinoma in sheep to evaluate radioimmunotherapy.

Review 7. Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer.